Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Comparative outcomes of posaconazole vs. voriconazole/isavuconazole for antifungal prophylaxis in neutropenic adults with Acute Myeloid Leukemia: A propensity-matched retrospective cohort study

Mohammad Salameh, Jamil Nazzal, Zaid Zahid et al. Nov 03, 2025 pp. 5191-5191 10.1182/blood-2025-5191

Abstract Background: Patients with acute myeloid leukemia (AML) undergoing chemotherapy are at high risk for invasive fungal infections (IFI...

A mammalian coacervate-based platform for high-efficiency gene editing in hematopoietic stem cells

Renxia Zhang, Peipei Zhu, Manman Lu et al. Nov 03, 2025 pp. 4186-4186 10.1182/blood-2025-4186

Abstract Gene editing in hematopoietic stem cells (HSCs) holds tremendous promise for treating inherited blood disorders such as sickle cell...

Distinct patterns of clonal hematopoiesis exist in a longevity enriched cohort

Salman Sadullah Usmani, Kith Pradhan, Tina Gao et al. Nov 03, 2025 pp. 1393-1393 10.1182/blood-2025-1393

Abstract Introduction The impact of age-associated clonal hematopoiesis (CH) on healthspan and lifespan remains unclear with some studies li...

Impact of the number of bridging therapy lines on outcomes after axi-cel in LBCL: A lysa study from the descar-T registry

Guillaume Manson, Cécile Pizot, Emmanuel Bachy et al. Nov 03, 2025 pp. 2745-2745 10.1182/blood-2025-2745

Abstract Introduction The optimal use of bridging therapy (BT) prior to anti-CD19 CAR T-cell therapy in large B-cell lymphoma (LBCL) remains...

ReInspire: A phase 2 study of mutant-selective PI3Kα inhibitor, RLY-2608, in adults and children with PIK3CA-related overgrowth spectrum and malformations driven by PIK3CA mutation

Shelley Crary, Joana Mack, Ahmad Al-Huniti et al. Nov 03, 2025 pp. 3092-3092 10.1182/blood-2025-3092

Abstract Background and Significance Somatic gain-of-function mutations in the PIK3CA gene can result in a range of vasc...

Contact-free single cell assay for assessing RBC mechanical properties using brillouin microscopy: Evaluation of anti-sickling therapeutics

Aishwarya Anand, Yogeshwari Ambekar, Stephen Rogers et al. Nov 03, 2025 pp. 6490-6490 10.1182/blood-2025-6490

Abstract Background: Brillouin microscopy is a non-contact, all-optical, label free technique, recently developed for biomechanical studies...

The impact of monocytic phenotype and NPM1-mutation status in Acute Myeloid Leukemia when treated with traditional induction chemotherapy compared to azacitidine and venetoclax

Michael Jones, Cailin Collins, Danica Wiredja et al. Nov 03, 2025 pp. 3478-3478 10.1182/blood-2025-3478

Abstract Introduction: Patients with acute myeloid leukemia (AML) with monocytic differentiation treated with azacitidine (aza) and venetocla...

IFN-α potentiates daratumumab response in multiple myeloma: A commpass study

Colton Dysart, Nathaniel Buteyn, Sophia Chaudhry et al. Nov 03, 2025 pp. 3936-3936 10.1182/blood-2025-3936

Abstract Multiple myeloma (MM) is the most common plasma cell dyscrasia, the second most common blood cancer, and a source of tremendous com...

Analysis of CD8 cytotoxic t-cells in patients with myelodysplastic syndrome (MDS) and T-cell large granulocyte lymphocytic leukemia (T-LGLL) reveal a distinct phenotype compared to those with t-lgll

Makenna May, Cassandra Duarte, Rosana Moreira Pereira et al. Nov 03, 2025 pp. 5610-5610 10.1182/blood-2025-5610

Abstract Background: MDS is a neoplasm that primarily affects older adults and can lead to bone marrow failure, and cytopenias. T-LGLL is an...

Blinatumomab versus high-dose chemotherapy in the first-line therapy of high-risk childhood B-cell acute lymphoblastic leukemia: The results of a Phase 3 trial of the cALL-pol consortium in Poland

Wojciech Michal Mlynarski, Pawel Laguna, Szymon Skoczeń et al. Nov 03, 2025 pp. 1576-1576 10.1182/blood-2025-1576

Abstract The Childhood Acute Lymphoblastic Leukemia in Poland (cALL-POL) consortium links all pediatric oncology centers in the country and...

Long-term outcomes in high-risk patients with chronic lymphocytic leukemia treated with targeted therapies in the real-world

Anna Petrackova, Zuzana Kubova, Dominika Ecsiova et al. Nov 03, 2025 pp. 3907-3907 10.1182/blood-2025-3907

Abstract Introduction: The development of targeted agents for chronic lymphocytic leukemia (CLL) has changed the paradigm for the treatment o...

Estimating the survival impact of not receiving CAR T-cell (CAR T) therapy when eligible in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in the United States (US)

Frederick Locke, Bradley Kievit, Genevieve Meier et al. Nov 03, 2025 pp. 4510-4510 10.1182/blood-2025-4510

Abstract Introduction: The therapeutic approach to relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in the United States h...

Impact of previous BCMA exposure: Evidence from practice outside of clinical trials to inform talquetamab sequencing

María-Jesús Blanchard, Marcos Lorenzo Perez, Ana Saus Carreres et al. Nov 03, 2025 pp. 2272-2272 10.1182/blood-2025-2272

Abstract BACKGROUND: Targeted immunotherapies have brought about remarkable advancements in the treatment of multiple myeloma (MM), particul...

All 19 subjects with transfusion-dependent β-thalassemia achieved transfusion independence after treatment with RM-001 (autologous HBG1/2 promoter-modified CD34+ hematopoietic stem and progenitor cells)

Rongrong Liu, Li Wang, Hui Xu et al. Nov 03, 2025 pp. 4308-4308 10.1182/blood-2025-4308

Abstract Background: RM-001 is a novel non-viral cell therapy for β-hemoglobinopathies that reactivates fetal hemoglobin (HbF) through ex vi...

Using large language models to identify frailty among older adults with blood cancer

Nicole Agaronnik, Thomas Sounack, Ameya Sanyal et al. Nov 03, 2025 pp. 2565-2565 10.1182/blood-2025-2565

Abstract Background Geriatric assessment (GA) is now recommended by the American Society of Clinical Oncology for all older adults with canc...

Aponermin-based regimen as bridging therapy prior to CAR-T cell therapy for relapsed/refractory multiple myeloma

Junru Liu, Juan Li Nov 03, 2025 pp. 7534-7534 10.1182/blood-2025-7534

Abstract Object To observe the efficacy and safety of Aponermin-based regimen utilized as bridging therapy before CAR-T cell therapy in pati...

Decoding the role of inflammatory signaling in shaping HSC heterogeneity and engraftment in gene therapy-treated β-thalassemia pediatric patients

Maria Rosa Lidonnici, Giulia Chianella, Nicole Mende et al. Nov 03, 2025 pp. 4309-4309 10.1182/blood-2025-4309

Abstract Stress conditions influence hematopoietic stem cell (HSC) fate and lineage output, underscoring hematopoietic flexibility to extern...

Efficacy and safety of recombinant adjuvanted zoster vaccine in patients with monoclonal gammopathies: A prospective study

Vasiliki Spiliopoulou, Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos et al. Nov 03, 2025 pp. 3985-3985 10.1182/blood-2025-3985

Abstract Background Patients with multiple myeloma (MM) are prone to infections due to immunosuppression, whereas they show impaired serologi...

Females affected by Hemophilia A: Data from the United States 8CHECK program

Jill Johnsen, Shelley Nakaya Fletcher, Lina Aires et al. Nov 03, 2025 pp. 535-535 10.1182/blood-2025-535

Abstract Introduction: In hemophilia A (HA), females are diagnosed using F8 genotype, factor VIII (FVIII) level, and bleeding symptom inform...

A simple, 3-factor pre-treatment score (Toranomon Prognostic Score) robustly stratifies progression risk in patients with relapsed/refractory large B-cell lymphoma receiving commercial CAR T-cell therapy: A real-world analysis

Rikako Tabata, Daisuke Kaji, Go Yamamoto et al. Nov 03, 2025 pp. 1942-1942 10.1182/blood-2025-1942

Abstract Background: Chimeric antigen receptor (CAR) T-cell therapy offers durable remissions for relapsed/refractory (R/R) large B-cell lym...

Efficacy, safety, and pharmacokinetics of alpelisib (ALP) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS): Epik-P4, a Phase II study

Alexandra J Borst, Denise M Adams, Juan C Lopez-Gutierrez et al. Nov 03, 2025 pp. 8227-8227 10.1182/blood-2025-8227

Abstract Background and Significance: PROS is a group of rare clinical syndromes caused by tissue-specific somatic mutations in the phosphat...

A phase I/II, open label, Study to evaluate safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis: Interim report of phase I results

Shahrier Hossain, Adam Sperling, Jacob Laubach et al. Nov 03, 2025 pp. 5808-5808 10.1182/blood-2025-5808

Abstract Background: Rapid and deep normalization of involved free light chains (iFLC) is necessary for organ response and attendant surviva...

Development of multi-targeting CAR-double-negative T cells for allogeneic immunotherapy in B-cell leukemia

Jessica López Espinosa, Juan Arteaga, Michele Nawata et al. Nov 03, 2025 pp. 2410-2410 10.1182/blood-2025-2410

Abstract Introduction Clinical breakthroughs achieved through Chimeric Antigen Receptor (CAR)-T cell therapy have revolutionized the treatme...

Gut microbiota alterations in myelodysplastic neoplasms are associated with immune dysfunction and the therapeutic mechanism of hypomethylating agents

Zhongxun Shi, Fei Huang, Yu Chen et al. Nov 03, 2025 pp. 7362-7362 10.1182/blood-2025-7362

Abstract Myelodysplastic neoplasms (MDS) represent a group of heterogeneous clonal disorders characterized by immune dysregulation in their...

Chinese pediatric cGvHD patients and caregivers perspectives: Patient journey and trial participation

Yanhui Luo, Ruixue Ma, Cecile Gousset et al. Nov 03, 2025 pp. 2678-2678 10.1182/blood-2025-2678

Abstract Background: Chronic graft-versus-host disease (cGvHD) is a major complication in pediatric hematopoietic stem cell transplantation...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page